NDRA

ENDRA Life Sciences Inc. (NDRA) | Rumor.io

ENDRA Life Sciences

NDRA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,900

Bullish sentiment (50-day avg)0%

Price to earnings ratio0.24

Market capitalization8.7M

Earnings per share-6.29

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-7M

Social

What share of all stock conversation is about NDRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 25

ENDRA Life Sciences ($NDRA) has agreed to merge with Noble Africa, a subsidiary of ASP Isotopes ($ASPI), in a deal that includes a $50M private placement.
The combined company will trade as NOBA on Nasdaq, with ASP Isotopes retaining an 89% stake, and ENDRA shareholders expected to own around 3% of the company.
The merger is seen as a strategic pivot for ENDRA, which will abandon its thermoacoustic imaging business and become a Nasdaq-listed helium platform, potentially transforming its market value.

Generated by AI

Sentiment

Of the messages about NDRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.12% -1.92
Bearish	—	—	—	21.88% +1.92

Bullish· Oct 13

ENDRA Life Sciences Inc. has innovative potential in the field of non-invasive liver disease diagnostics, targeting the NAFLD/NASH market and the growing demand for metabolic disease diagnostics.
The company is advancing its TAEUS ultrasound tech for non-invasive liver imaging, which is expected to drive major upside with a $50 target price.
ENDRA Life Sciences Inc. has a low float and fresh volume, fueling its biotech momentum and making it a strong candidate for further price appreciation.

Bearish· Oct 13

$NDRA's private placement may lead to the scrapping of its S-1 offer, potentially causing further selling pressure.
The company's dilution concerns, including the issuance of a small offering with limited funds, have raised doubts about its legitimacy and ability to execute its business plan.
$NDRA's low float and history of rapid price movements have created a volatile trading environment, making it a high-risk investment for bears and bulls alike.

Generated by AI

Topics

Of the messages about NDRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	80.36%
Technical Analysis	—	—	—	14.65%
Analysts	—	—	—	2.72%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	2.27%

Announcements· Oct 13

ENDRA Life Sciences Inc. ($NDRA) announced an at-market private placement of up to $14.4 million to launch a digital asset treasury strategy managed by Arca.
The company plans to use the funding to establish digital asset treasury operations, accumulate cryptocurrencies, and support the completion of its pilot TAEUS imaging validation study for metabolic dysfunction-associated liver disease.
The private placement is expected to close on or about October 14, 2025, and may be a catalyst for further growth, given the company's low float and recent analyst coverage.

Technical Analysis· Jul 8

$NDRA breaks out above $9.20, with strong upside potential due to EMA overlay and rebound from VWAP, with a possible maximum upside above $15.
The stock has confirmed a U.S. patent for its RF applicator, with a 133% increase, and a clean break above $11.96 could open a momentum window.
The support line at $7.56 is fragile, and a break below it could lead to a price touch of the $5 zone, with caution advised due to the uncertain nature of the support.

Generated by AI

Community

Of the messages about NDRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	25%	30.38%
Newcomers	—	—	75%	69.62%

Regulars· Jun 17

The regular participant had a mixed trading day, closing small green thanks to a gain in ENDRA Life Sciences Inc. ($NDRA) but feeling the need to slow down and be more selective in the market.
ENDRA Life Sciences Inc. ($NDRA) saw a significant increase in trading volume, trading 917% above average, and its stock price rose 33.11%.
L1 Capital Global Opportunities Master Fund, Ltd. filed a Form SC 13G with the SEC, disclosing a stake in ENDRA Life Sciences Inc. ($NDRA) following its significant price increase.

Newcomers· Oct 14

New investors are focused on ENDRA Life Sciences Inc.'s recent stock price drop, with a 17.12% decrease to $6.730 pre-market.
These newcomers are highlighting the company's progress in achieving an imaging breakthrough, reaching a cash milestone, and executing a product go-to-market strategy.
Investors are calling for ENDRA to demonstrate clinical and commercial follow-through to support their growth story.

Generated by AI

ANN ARBOR, Mich., August 17, 2026--ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or the "Company"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), reported financial results for the quarter ended June 30, 2026, and provided a business update.

1mo agoYahoo Finance

12 Health Care Stocks Moving In Tuesday's After-Market Session - ENDRA Life Sciences (NASDAQ:NDRA), Apime

Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-market session. The market value of their outstanding shares is at $6.2 million. Apimeds Pharmaceuticals (AMEX:APUS)

2mo agoBenzinga

ASP Isotopes Maps Noble Africa Listing as Helium Project Nears Production

ASP Isotopes (NASDAQ:ASPI) executives outlined plans to create a publicly listed helium and liquefied natural gas platform through Noble Africa, emphasizing Renergen’s South African helium resource, expected near-term production milestones and the proposed merger with ENDRA Life Sciences. Paul Mann

2mo agoYahoo Finance

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

DALLAS & ANN ARBOR, Mich., July 17, 2026--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes" or "ASPI"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) ("ENDRA" or "NDRA"), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that RedChip Companies will host an investor webinar

2mo agoYahoo Finance

Also Discussed

Investors talking about NDRA also mention

#	Name	Attention
1	PRST - Presto Automation, Inc.	——
2	LPTV - Loop Media, Inc.	——
3	Akoustis Technologies Inc.AKTS	0%new
4	Nauticus Robotics Inc.KITT	0%0
5	ZCAR - Zoomcar Holdings, Inc.	——
6	Crown Electrokinetics Corp.CRKN	0%0
7	SOBR Safe, Inc.SOBR	0%0
8	BRSH - Bruush Oral Care Inc.	——
9	CYNGN Inc.CYN	0%0
10	Mustang Bio Inc.MBIO	0%0

ENDRA Life Sciences Inc.

Healthcare
Diagnostics & Research

ENDRA Life Sciences Inc. is a medical technology company focused on enhancing clinical diagnostic ultrasound through its Thermo Acoustic Enhanced Ultrasound (TAEUS) platform. The company develops non-invasive imaging tools designed to help clinicians assess tissue composition, temperature, and blood flow at the point of care. Its current work centers on liver fat measurement for metabolic disease evaluation, including applications related to non-alcoholic fatty liver disease, as well as broader uses in vascular imaging, tissue perfusion analysis, and temperature monitoring during minimally invasive procedures. ENDRA Life Sciences also addresses medical-device needs in settings where compact, lower-cost imaging solutions can complement traditional ultrasound and other advanced modalities. Based in Ann Arbor, Michigan, the company operates in the healthcare technology sector and serves the medical imaging market with products aimed at improving diagnostic precision and accessibility.

Website

Location

3600 Green Court

Ann Arbor, MI, 48105-1570

United States

Social

What share of all stock conversation is about NDRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 25

ENDRA Life Sciences ($NDRA) has agreed to merge with Noble Africa, a subsidiary of ASP Isotopes ($ASPI), in a deal that includes a $50M private placement.
The combined company will trade as NOBA on Nasdaq, with ASP Isotopes retaining an 89% stake, and ENDRA shareholders expected to own around 3% of the company.
The merger is seen as a strategic pivot for ENDRA, which will abandon its thermoacoustic imaging business and become a Nasdaq-listed helium platform, potentially transforming its market value.

Generated by AI

Sentiment

Of the messages about NDRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	78.12% -1.92
Bearish	—	—	—	21.88% +1.92

Bullish· Oct 13

ENDRA Life Sciences Inc. has innovative potential in the field of non-invasive liver disease diagnostics, targeting the NAFLD/NASH market and the growing demand for metabolic disease diagnostics.
The company is advancing its TAEUS ultrasound tech for non-invasive liver imaging, which is expected to drive major upside with a $50 target price.
ENDRA Life Sciences Inc. has a low float and fresh volume, fueling its biotech momentum and making it a strong candidate for further price appreciation.

Bearish· Oct 13

$NDRA's private placement may lead to the scrapping of its S-1 offer, potentially causing further selling pressure.
The company's dilution concerns, including the issuance of a small offering with limited funds, have raised doubts about its legitimacy and ability to execute its business plan.
$NDRA's low float and history of rapid price movements have created a volatile trading environment, making it a high-risk investment for bears and bulls alike.

Generated by AI

Topics

Of the messages about NDRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	80.36%
Technical Analysis	—	—	—	14.65%
Analysts	—	—	—	2.72%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	2.27%

Announcements· Oct 13

ENDRA Life Sciences Inc. ($NDRA) announced an at-market private placement of up to $14.4 million to launch a digital asset treasury strategy managed by Arca.
The company plans to use the funding to establish digital asset treasury operations, accumulate cryptocurrencies, and support the completion of its pilot TAEUS imaging validation study for metabolic dysfunction-associated liver disease.
The private placement is expected to close on or about October 14, 2025, and may be a catalyst for further growth, given the company's low float and recent analyst coverage.

Technical Analysis· Jul 8

$NDRA breaks out above $9.20, with strong upside potential due to EMA overlay and rebound from VWAP, with a possible maximum upside above $15.
The stock has confirmed a U.S. patent for its RF applicator, with a 133% increase, and a clean break above $11.96 could open a momentum window.
The support line at $7.56 is fragile, and a break below it could lead to a price touch of the $5 zone, with caution advised due to the uncertain nature of the support.

Generated by AI

Community

Of the messages about NDRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	25%	30.38%
Newcomers	—	—	75%	69.62%

Regulars· Jun 17

The regular participant had a mixed trading day, closing small green thanks to a gain in ENDRA Life Sciences Inc. ($NDRA) but feeling the need to slow down and be more selective in the market.
ENDRA Life Sciences Inc. ($NDRA) saw a significant increase in trading volume, trading 917% above average, and its stock price rose 33.11%.
L1 Capital Global Opportunities Master Fund, Ltd. filed a Form SC 13G with the SEC, disclosing a stake in ENDRA Life Sciences Inc. ($NDRA) following its significant price increase.

Newcomers· Oct 14

New investors are focused on ENDRA Life Sciences Inc.'s recent stock price drop, with a 17.12% decrease to $6.730 pre-market.
These newcomers are highlighting the company's progress in achieving an imaging breakthrough, reaching a cash milestone, and executing a product go-to-market strategy.
Investors are calling for ENDRA to demonstrate clinical and commercial follow-through to support their growth story.

Generated by AI

ENDRA Life Sciences

Social

Jun 25

Sentiment

Bullish· Oct 13

Bearish· Oct 13

Topics

Announcements· Oct 13

Technical Analysis· Jul 8

Community

Regulars· Jun 17

Newcomers· Oct 14

News

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Tuesday's After-Market Session - ENDRA Life Sciences (NASDAQ:NDRA), Apime

ASP Isotopes Maps Noble Africa Listing as Helium Project Nears Production

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

Also Discussed

ENDRA Life Sciences Inc.

Company Information

Location

News

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

12 Health Care Stocks Moving In Tuesday's After-Market Session - ENDRA Life Sciences (NASDAQ:NDRA), Apime

ASP Isotopes Maps Noble Africa Listing as Helium Project Nears Production

Join the Live Investor Webinar for Noble Africa, the Proposed ASP Isotopes Spin-Out Creating a Public Helium Company

Also Discussed

Social

Jun 25

Sentiment

Bullish· Oct 13

Bearish· Oct 13

Topics

Announcements· Oct 13

Technical Analysis· Jul 8

Community

Regulars· Jun 17

Newcomers· Oct 14